Upregulation of osteopontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin

Diabetes

Volumn 47, Issue 9, 1998, Pages 1512-1518

  Fischer, Jens W ^c,d   Tschöpe, Carsten ^b   Reinecke, Alexander ^a   Giachelli, Cecilia M ^c   Unger, Thomas ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; OSTEOPONTIN;

ANIMAL EXPERIMENT; ARTICLE; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION RATE; KIDNEY CORTEX; KIDNEY FAILURE; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES;

EID: 0031711338     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.47.9.1512     Document Type: Article

References (64)

1. Grenfell A, Bewick M, Snowden S, Watkins PJ, Parsons V: Renal replacement for diabetic patients: experience at King's College Hospital 1980-1989. Q J Med 307-308:861-874, 1992
2. Andersen AR, Christiansen JS, Andersen JK, Kleiner S, Deckert T: Diabetic nephropathy in type I (insulin-dependent) diabetes: an epidemiological study. Diabetologia 25:496-501, 1983
3. U.S. Renal Data System: UDRS Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive Kidney Diseases, 1992
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
5. Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M: Beneficial effects of angiotensia converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ 293:471-474, 1986
6. Parving HH, Hommel E, Smidt UM: Protection of kidney function and decrease in albuminuria by captopril in insulin depedent diabetics with nephropathy. BMJ 297:1086-1091, 1988
7. Melbourne Diabetic Nephropathy Study Group: Comparison between perindopril and nifedipine in hypertensive and normotensive patients with microalbuminuria. Br Med J 302:210-216, 1991
8. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz, FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 74:1143-1155, 1984
9. Ziyadeh FN, Goldfarb S: The renal tubulointerstitium in diabetes mellitus. Kidney Int 39:464-475, 1991
10. Bohle A, Mackensen-Haen S, von-Gise H: Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney: a morphometric contribution. Am J Nephrol 7:421-433, 1987
11. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM: Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 92:1686-1896, 1993
12. Ikeda T, Shirasava T, Esaki Y, Yoshiki S, Hirokawa K: Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 92:2814-2820, 1993
13. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL: High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 93:2393-2402, 1994
14. Murry, CE, Giachelli CM, Schwartz SM, Vracko R: Macrophages express osteopontin during repair of mycardial necrosis. Am J Pathol 145:1450-1462, 1994
15. Giachelli CM, Pichler R, Lombardi D, Denhardt DT, Alpers CE, Schwartz SM, Johnson RJ: Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int 45:515-524, 1994
16. Pichler R, Giachelli CM, Lombardi D, Pippin J, Gordon K, Alpers CE, Schwartz SM, Johnson RJ: Tubulointerstitial disease in glomerulonephritis: potential role of osteopontin (uropontin). Am J Pathol 144:915-926, 1994
17. Oldberg A, Franzen A, Heinegard D: Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A 83:8819-8823, 1986
18. Prince CW, Oosawa T, Butler WT, Tomana M, Bhown AS, Bhown M, Schrohenloher RE: Isolation, characterization and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chem 262:2900-2909, 1987
19. Heinegard D, Hultenby K, Oldberg A, Reinhold F, Wendel M: Macromolecules in bone matrix. Connect Tissue Res 21:3-11, 1989
20. Lopez CA, Hoyer JR, Wilson PD, Waterhouse P, Denhardt DT: Heterogeneity of osteopontin expression among nephrons in mouse kidneys and enhanced expression in sclerotic glomeruli. Lab Invest 69:355-363, 1993
21. Giachelli CM, Bae N, Lombardi D, Majesky M, Schwartz SM: Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2ar). Biochem Biophys Res Commun 177:867-873, 1991
22. Brown LF, Berse B, Van de Water L, Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, Dvorak HF, Senger DR: Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell 3:1169-1180, 1992
23. Yu XQ, Nikolic-Paterson DJ, Mu W, Giachelli CM, Atkins RC, Johnson RJ, Lan HY: A functional role for osteopontin in experimental crescentic glomerulonephritis in the rat. Proc Assoc Am Phys 110:50-64, 1998
24. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M: Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 152:353-358, 1998
25. Rogers SA, Padanilam BJ, Hruska KA, Giachelli CM, Hammerman MR: Metanephric osteopontin regulates nephrogenesis in vitro. Am J Physiol 272:F469-F476, 1997
26. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke S, Breipohl G, Konig W, Knolle J: Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 102:769-773, 1991
27. Kúhnle HF, Linzmeier P, Doerge L: Determination of glomerular filtration rate in rats. In Experimental and Genetic Rat Models of Chronic Renal Failure Gretz N, Strauch M Eds. Basel, Krager, 1993, p. 331-336
28. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM: Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 74:214-224, 1994
29. Dijkstra CD, Dopp EA, Joling P, Kraal F: The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2, and ED3. Immunology 54:589-599, 1985
30. Hutchison FN, Cui X, Webster SK: The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin. J Am Nephrol 6:1216-1222, 1995
31. Padanilan BJ, Martin DR, Hammerman MR: Insulin-like growth factor I-enhanced renal expression of osteopontin after acute ischemic injury in rat. Endocrinology 137:2133-2140, 1996
32. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, Schwartz SM: Renal injury from angiotensin II-mediated hypertension. Hypertension 19:464-474, 1992
33. Gadeau A, Campan M, Millet D, Candresse T, Desgranges C: Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler Thromb 13:120-125, 1993
34. Anderson S, Jung FF, Ingelfinger JR: Renal renin angiotensin system in diabetes: functional, immunohistochemical and molecularbiological correlations. Am J Physiol 165:F477-F486, 1993
35. Malyankar U, Almeida M, Johnson RJ, Pichler RH, Giachelli CM: Osteopontin regulation in cultured rat renal epithelial cells. Kidney Int 51:1766-1773, 1997
36. Scicli AG, Carretero OA: Renal Kallikrein-kinin syatem. Kidney Int 29:120-130, 1986
37. Majima M, Katori M: Approaches to the development of novel antihypertensive drugs: crucial role of the renal kallikrein-kinin system. Trends Pharmacol Sci 1 16:239-246, 1995
38. Siragy HM, Jaffa AA, Margolius HS: Bradykinin B2 receptor modulates renal prostaglandin E2 and nitric oxide. Hypertension 29:757-762, 1997
39. Fitzgibbon WR, Jaffa AA, Mayfield RK, Ploth DW: Role of kinins in the renal response to enalaprilat in normotensive and hypertensive rats. Hypertension 27:235-244, 1996
40. Tschöpe C, Gavriluk V, Reinecke A, Seidl U, Riester U, Hilgenfeldt U, Ritz E, Unger TH: Bradykinin excretion is increased in severely hyperglycemic streptozotocin-diabetic rats. Immunopharmacology 33:344-348, 1996
41. Burch RM, Kyle DJ: Recent developments in the understanding of bradykinin receptors. Life Sci 50:829-838, 1992
42. Burch RM, Axelrod J: Dissociation of bradykinin-induced prostaglandin formation from phosphatidylinositol turnover in Swiss 3T3 fibroblasts: evidence for G protein regulation of phospholipase A2. Proc Natl Sci U S A 84:6374-6378, 1987
43. Zugaza JL, Waldron RT, Sinnett-Smith J, Rozengurt E: Bombesin, vasopressin, endothelin, bradykinin, and platelet-derived growth factor rapidly activate protein kinase D through a protein kinase C-dependent signal transduction pathway. J Biol Chem 272:23952-23960, 1997
44. Middleton JP, Dunham CB, Onorato JJ, Sens DA, Denis VW: Protein kinase A, cytosolic calcium, and phosphate uptake in human proximal renal cells. Am J Physiol 257:F631-F638, 1989
45. Fleming I, Busse R: Tyrosine phosphorylation and bradykinin-induced signaling in endothelial cells. Am J Cardiol 80:102A-109A, 1997
46. Kennedy C, Proulx PR, Hébert RL: Bradykinin-induced translocation of cytoplasmic phospholipase A2 in MDCK cells. Can J Physiol Pharmacol 75:563-567, 1997
47. Kennedy CR, Proulx PR, Hébert RL: Role of PLA2, PLC, and PLD in bradykinin-induced release of arachidonic acid in MDCK cells. Am J Physiol 271:C1064-C1072, 1996
48. Xing M, Tao L, Insel PA: Role of extracellular signal-regulated kinase and PKC alpha in cytosolic PLA2 activation by bradykinin in MDCK-D1 cells. Am J Physiol 272:C1380-C1387, 1997
49. el-Dahr SS, Dipp S, Yosipiv IV, Baricos WH: Bradykinin stimulates c-fos expression. AP-1-DNA binding activity and proliferation of rat glomerular mesangial cells. Kidney Int 50:1850-1855, 1996
50. Rafidi K, Simkina I, Johnson E, Moore MA, Gerstenfeld LC: Characterization of the chicken osteopontin-encoding gene. Gene 140:103-169, 1994
51. Zhang Q, Wrana JL, Sodek J: Characterization of the promoter region of the porcine opn (osteopontin, secreted phosphoprotein 1) gene: identification of positive and negative regulatory elements and a 'silent' second promoter. Eur J Biochem 207:649-659, 1992
52. Seitz PK, Zhang RW, Simmons DJ, Cooper CW: Effects of C-terminal parathyroid hormone-related peptide on osteoblasts. Miner Electrolyte Metab 21:180-183, 1995
53. Dey NB, Boerth JN, Murphy-Ulrich JE, Chang PL, Prince CW, Lincoln TM: Cyclic GMP-dependent protein kinase inhibits osteopontin and thrombospondin production in rat aortic smooth muscle cells. Circ Res 82:139-146, 1998
54. Partridge NC, Bloch SR, Pearman AT: Signal transduction pathways mediating parathyroid hormone regulation of osteoblastic gene expression. J Cell Biochem 55:321-327, 1994
55. Daiter E, Omigbodun A, Wang S, Walinsky D, Strauss JF, Hoyer JR, Coutifaris C: Cell differentiation and endogenous cyclic adenosine 3′,5′-monophosphate regulate osteopontin expression in human trophoblasts. Endocrinology 137:1785-1790, 1996
56. Turner G, Coates P, Warren S, Woodhead JS, Peters JR: Proximal tubular reabsorption of growth hormone and sodium/fluid in normo- and microalbuminuric insulin-dependent diabetes mellitus. Acta Diabetol 34:27-32, 1997
57. Galanti LM, Jamart J, Dell'omo J, Donckier J: Comparison of urinary excretion of albumin, alpha 1 microglobulin and retinol-binding protein in diabetic patients. Diabetes Metab 22:324-330, 1996
58. O'Brien SF, Watts GF, Powrie JK, Shaw KM, Miller NJ: Lipids, lipoproteins, antioxidants and glomerular and tubular dysfunction in type 1 diabetes. Diabetes Res Clin Pract 32:81-90, 1996
59. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 74:1143-1155, 1984
60. Patarca R, Freeman GJ, Singh P, Wei FY, Durfee T, Blattner F, Regnier DC, Kozak CA, Mock BA, Morse HC III, Jerrells TR, Cantor H: Structural and functional studies of the early T lymphocyte activation (Eta-1) gene. J Exp Med 170:145-101, 1989
61. Singh RP, Patarca R, Schwartz J, Cantor II: Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo. J Exp Med 171:1931-1942, 1990
62. Ophascharoensuk V, Giachelli CM, Liaw L, Shankland SJ, Couser WG, Johnson RJ: Osteopontin mediates early macrophage influx in renal interstitial inflammation: a study in osteopontin knockout mice. J Am Soc Nephrol 8:481A, 1998
63. Young B, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser WG: Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 47:935-944, 1990
64. Hwang S, Lopez CA, Heck DE, Gardner CR, Laskin DL, Laskin JD, Denhardt DT: Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem 209:711-715, 1994